Aclaris Therapeutics price target lowered to $29 from $32 at BTIG

BTIG analyst Julian Harrison lowered the firm’s price target on Aclaris Therapeutics to $29 from $32 and keeps a Buy rating on the shares. Zunsemetinib did not meet the primary or key secondary efficacy endpoints in the Phase 2 hidradenitis suppurativa trial, but the firm views the current stock action as an attractive entry point ahead of multiple data events expected later this year, the analyst tells investors in a research note.